{"id":"NCT03351478","sponsor":"Lexicon Pharmaceuticals","briefTitle":"Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin","officialTitle":"A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Participants With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-27","primaryCompletion":"2019-05-16","completion":"2019-05-16","firstPosted":"2017-11-22","resultsPosted":"2021-05-11","lastUpdate":"2021-05-11"},"enrollment":770,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Sotagliflozin","otherNames":["SAR439954"]},{"type":"DRUG","name":"Empagliflozin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sotagliflozin 400 mg","type":"EXPERIMENTAL"},{"label":"Empagliflozin 25 mg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to demonstrate the superiority of sotagliflozin versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control on a DPP4(i) with or without metformin.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"Sotagliflozin 400 mg","deltaMin":-0.7,"sd":0.1},{"arm":"Empagliflozin 25 mg","deltaMin":-0.8,"sd":0.1},{"arm":"Placebo","deltaMin":-0.3,"sd":0.1}],"pValues":[{"comp":"OG000 vs OG002","p":"< 0.0001"},{"comp":"OG000 vs OG001","p":"0.145"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":24},"locations":{"siteCount":160,"countries":["United States","Bulgaria","Canada","Czechia","France","Italy","Latvia","Mexico","Russia","Slovakia","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":307},"commonTop":["Nasopharyngitis","Diarrhoea","Headache","Hyperglycaemia","Urinary tract infection"]}}